ChemoCentryx (CCXI) Reports Withdrawal of Phase II-Based CMA Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for 4Q19 – StreetInsider.com

ChemoCentryx (CCXI) Reports Withdrawal of Phase II-Based CMA Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for 4Q19 – StreetInsider.com

ChemoCentryx (CCXI) Reports Withdrawal of Phase II-Based CMA Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for 4Q19 – StreetInsider.com
Published on 2019-01-24